Blackrock Group Ltd buys $2,099,760,691 stake in Pfizer (PFE)

Pfizer (PFE) : Blackrock Group Ltd scooped up 552,493 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 60,027,464 shares of Pfizer which is valued at $2,099,760,691.Pfizer makes up approximately 1.05% of Blackrock Group Ltd’s portfolio.

Other Hedge Funds, Including , Columbia Partners L L C Investment Management boosted its stake in PFE in the latest quarter, The investment management firm added 1,238 additional shares and now holds a total of 48,701 shares of Pfizer which is valued at $1,703,561. Pfizer makes up approx 0.12% of Columbia Partners L L C Investment Management’s portfolio.Courier Capital Corp reduced its stake in PFE by selling 2,105 shares or 3.1% in the most recent quarter. The Hedge Fund company now holds 65,794 shares of PFE which is valued at $2,321,870. Pfizer makes up approx 0.45% of Courier Capital Corp’s portfolio.Swedbank reduced its stake in PFE by selling 482,837 shares or 10.25% in the most recent quarter. The Hedge Fund company now holds 4,227,504 shares of PFE which is valued at $155,318,497. Pfizer makes up approx 1.25% of Swedbank’s portfolio.Reinhart Partners reduced its stake in PFE by selling 9,280 shares or 54.41% in the most recent quarter. The Hedge Fund company now holds 7,775 shares of PFE which is valued at $285,654. Pfizer makes up approx 0.03% of Reinhart Partners’s portfolio.Capital Analysts reduced its stake in PFE by selling 690 shares or 2.65% in the most recent quarter. The Hedge Fund company now holds 25,375 shares of PFE which is valued at $929,740. Pfizer makes up approx 0.18% of Capital Analysts’s portfolio.

Pfizer closed down -0.21 points or -0.60% at $34.98 with 1,95,68,121 shares getting traded on Friday. Post opening the session at $35.06, the shares hit an intraday low of $34.825 and an intraday high of $35.12 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.